<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

2 min read

Continuing the Ascent: Q322 US Surgical Matrices Market Recap

By Doug Devens on 1/9/23 10:47 AM

Biosynthetic hernia matrices continue their ascent and Xenograft hernia matrices grow, thanks to TELA Bio.

As elective surgical procedures settle into pre-pandemic levels, the US Surgical Matrices Market resumed trends that had begun prior to Q322, gaining +2.4% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) have been trading share positions in the last few quarters and now once again AbbVie has first place in the Q322 Surgical Matrices market despite of a -5.4% YoY decline, with BD In second place.

Among the many topics covered in detail in our comprehensive Q322 US Surgical Matrices Market Recap* are:

Continue Reading
2 min read

New Products and Easier Comps Drive US Growth: Q322 Trauma Market Recap

By Natasha Weeks on 1/3/23 9:30 AM

Despite declining OUS results, the US Trauma Market experienced healthy growth attributed to adoption of new products.

While OUS results declined in Q322 due to foreign currency headwinds and China’s value-based pricing, the US drove the overall market through product penetration and easier comps due to the Q321 COVID waves that impacted procedural volumes last year. Companies posted healthy US growth, attributing new products for driving growth, with plans for additional launches in Q4 and 2023.

Among the many topics covered in detail in our comprehensive Q322 Trauma Market Recap* are:

Continue Reading
2 min read

Wrestling with Issues and Headwinds: Q322 Neuromodulation Market Recap

By Anne Staylor on 12/29/22 9:30 AM

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-environmental issues and currency headwinds

Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.

Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are:

Continue Reading
2 min read

Trends in ADM Use from ASPS 2022

By Doug Devens on 12/20/22 9:30 AM

Surgeons are concerned about the cost of breast matrices in an increasingly restrictive environment, but alternatives may be on the horizon according to key discussions at the 2022 Plastic Surgery: The Meeting.

Breast matrices are used to cover breast implants in breast reconstruction and cosmetic breast surgeries. The matrices have become in effect standard of care in these surgeries, though they do not have FDA-approved indications for breast reconstruction or cosmetic breast surgeries. Moreover, the FDA has in recent years, issued warning letters and communications related to breast matrices. In 2015, the FDA issued warning letters reminding several companies that they did not ...

To read the complete "Trends in ADM Use from ASPS 2022" article by Doug Devens, SmartTRAK's Product Director/Sr. Analyst - Wound, in which  he shares observations from the ASPS sessions and the potential implications for the Breast Matrices Market, just click the following link.

Download the complete "Trends in ADM" Article

Continue Reading
2 min read

A Tidal Wave of Competitors: Q322 CAS Spine Market Recap

By Shelly Caruso on 12/19/22 6:41 PM

Q322 sees a tidal wave of new robotic spine surgery competitors as well as data-driven initiatives under development by a host of companies in the market for spine enabling tech.

Q322 was nothing short of a tidal wave of competitive entrants to the US Spine Robotic Surgery space. Medtronic* (MDT) and  Globus* remain top players as OUS companies like France’s  eCential Robotics* and Taiwan’s  Point Robotics MedTech* set their sights on the US market. The Q322 WW CAS Spine Market was up, according to  SmartTRAK Financial Dashboard. MDT remained the market leader with 49.0% share, followed by Globus and other enabling tech competitors like Brainlab* and Stryker* (SYK).

Among the many topics covered in detail in our comprehensive Q322 CAS Spine Market Recap* are:

Continue Reading
2 min read

Raging Like a Beast: Q322 US Joint Fluid Replacement Market Recap

By Freddy Buntoum on 12/16/22 9:30 AM

CMS Reimbursement changes raging like a beast to belabor several HA market players

For Q322, the true impact of CMS reimbursement changes was blatantly apparent, with the US Joint Fluid Replacement Market showing an overall lackluster revenue performance, with a YoY decline of -4.7% vs Q321, according to SmartTRAK Financial Dashboard. As if the new CMS regulations were not enough, the swing toward negative growth was also driven by hyaluronic (HA) companies battling for product placement, preferred formulary status with private payers, overall inflation, and still to a certain degree, supply chain-related issues stemming from COVID-19 and subsequent waves of the different variants. Aggregate revenue being in the red for the third quarter of 2022 was mainly the result of negative YoY growth across three of the four HA segments. Still, with an anticipated hard push to more positive year-end results, the US Joint Fluid Replacement Market is trending toward achieving on or ever so slightly above  SmartTRAK’s US Joint Fluid Replacement Market Overview revenue projections

Among the many topics covered in detail in our comprehensive Q322 US Joint Fluid Replacement Market Recap* are:

Continue Reading
3 min read

Big Data is Dead. This is the Time for SmartTRAK Insights.

By Sharon O'Reilly on 12/12/22 1:53 PM


As the CEO of SmartTRAK, I understand Medtech executives often drown in data and need quick, easy access to market insights from a trusted source. According to a Forbes article Big Data is Dead. Long Live Smart Data, the “more Data-is-Better” era is over, and it is time for Smart Data. And that means a SmartTRAK subscription is more important than ever.

SmartTRAK is the Medtech’s industry first and only “Insights-as-a-Service(IaaS) solution, curating data from hundreds of data sources, including public and commercial databases as well as extensive attendance and coverage of industry conferences. Our team of industry experts and data scientists do the work for our customers, providing actionable intelligence and insights from data that is already cleaned, verified and featurized. Our proprietary data curation methodology powers the SmartTRAK platform, which can be accessed on demand 24x7 across the enterprise.

Continue Reading
3 min read

Bolt Navigation: Simplifying Spinal Navigation-An Interview with CEO Patrick West

By Shelly Caruso on 12/12/22 10:00 AM

SmartTRAK interviews Bolt Navigation CEO Patrick West to learn more about the Company and its potentially disruptive solution for streamlined spinal navigation.

One of the most exciting enabling technologies on display at the recent North American Spine Society (NASS) 2022 annual meeting in Chicago was the Bolt Navigation System, a novel, FDA-pending technology developed by Bolt Navigation to simplify spinal navigation. Designed by a practicing neurosurgeon, Bolt utilizes a software application to leverage the positional guidance inherent in an iPhone for intraoperative spine screw planning and placement guidance. The system works without a reference frame and can be used with a patient's diagnostic MRI or CT and a single C-arm shot once the patient is positioned. It is implant agnostic and can be attached to almost any instrument.

To find out more about Bolt Navigation and this potentially disruptive solution for streamlined spinal navigation, listen to SmartTRAK’s interview with CEO Patrick West in the following video (30:47 min). A link to a transcript of the complete interview is also provided below.

Continue Reading
2 min read

Elective Procedure Volumes Improving: Q322 Total Joints Market Trends

By Lisa Mahan on 12/8/22 9:30 AM

Even stronger foreign exchange headwinds inhibit revenue growth from steadily improving elective procedural trends 

Procedural volumes appear to be steadily improving overall as the COVID pandemic comes close to the end of its third year. Despite the return of procedures, foreign currency headwinds in Q322 strengthened, negatively impacting reported revenue growth for most companies in markets outside the US. Global companies with a strong international presence were most adversely affected.

Among the many topics covered in detail in our comprehensive Q322 Total Joints Market Recap* are:

  • Complete Q322 Total Joints Market Overview and Highlights
  • SmartTRAK's Expert Analysis and Insights
  • All Company News, Revenues, Data, Charts and Shares
  • Improving Procedural Volumes Leaning into Strengthening Foreign Exchange Headwinds
  • Hips: Muscle-Sparing Solutions and New Products Driving Growth
  • Knees: Assistive Tech Driving Implant Pull-Through
  • Q322 Regulatory Highlights
Continue Reading
3 min read

SmartTRAK is Seeking a Senior Analyst: Spine and OrthoBiologics/Regen

By Sharon O'Reilly on 12/6/22 4:08 PM

Do you love keeping up with the latest trends in the Spine and OrthoBiologics/Regen medicine markets? Are you a closet investigative reporter who loves researching and analyzing what’s going on in the market? Are you looking for a position that leverages your industry knowledge, expertise and connections in new ways? If you are a current or former marketing, market research or business development professional who has worked with one of the major orthopedic/spine companies and looking for a career change, we would love to talk with you.

We are looking to strengthen our SmartTRAK Spine and OrthoBiologics/Regen modules with the addition of a qualified person with industry specific experience. All SmartTRAK analysts are former marketing, business development or R&D professionals with one of the major orthopedic/spine suppliers and, in fact, most have come to us via recommendations from our subscribers, as well as those in the industry. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add we can offer SmartTRAK subscribers.

We are looking for someone with Spine and OrthoBiologics/Regen industry experience who is interested in working full-time. Click the button below to learn more and apply. Learn More and Apply

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles